Litigation Details for Pernix Ireland Pain Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Pernix Ireland Pain Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Docket		Date Filed	2016-03-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:145 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	9,265,760; 9,326,982; 9,333,201; 9,339,499; 9,421,200; 9,433,619
Link to Docket	External link to docket

Details for Pernix Ireland Pain Ltd. v. Actavis Laboratories FL, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-03-04	121		Ph.D. Regarding the Invalidity of U.S. Patent Nos. 9,265,760 and 9,339,499 filed by Actavis Laboratories… 4 March 2016 1:16-cv-00138-GMS Patent None District Court, D. Delaware	External link to document
2016-03-04	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,265,760. (nmb) (Entered: 03… 4 March 2016 1:16-cv-00138-GMS Patent None District Court, D. Delaware	External link to document
2016-03-04	85		.S. Patent Nos. 9,265,760 (the '"760 Patent"), 9,326,982 (the "'982 Patent"… ORDER Construing the Terms of U.S. Patent Nos. 9,265,760, 9,326,982, 9,333,201, 9,339,499, 9,421,… ORDER CONSTRUING THE TERMS OF U.S. PATENT NOS. 9,265,760, 9,326,982, 9,333,201, …9,333,201 (the "'201 Patent"), 9,339,499 (the "'499 Patent"), 9,421,200 (the "…"'200 Patent"), and 9,433,619 (the "'619 Patent"): I. The	External link to document

Pernix Ireland Pain Ltd. v. Actavis Laboratories FL, Inc.: Litigation Summary and Patent Analysis

Last updated: August 20, 2026

Pernix Ireland Pain Ltd. sued Actavis Laboratories FL, Inc. in the District of Delaware after Actavis filed an abbreviated new drug application seeking approval for a generic version of Zohydro ER, an extended-release hydrocodone product. The case concerned Pernix’s Orange Book-listed formulation patents, including U.S. Patent Nos. 8,808,737 and 9,192,644. The dispute was an ANDA Paragraph IV case under the Hatch-Waxman Act. The publicly available record does not establish a final merits ruling holding the asserted patents invalid or unenforceable.

What drug and patents were involved in the Pernix v. Actavis case?

The litigation involved Zohydro ER, an extended-release hydrocodone bitartrate capsule marketed by Pernix Therapeutics and related entities. Zohydro ER received FDA approval in October 2013 under NDA No. 202880. The product was approved for the management of pain severe enough to require a daily, around-the-clock, long-term opioid treatment when alternative treatments are inadequate (FDA, 2013).

The asserted patent estate focused on extended-release hydrocodone formulations.

Patent	General subject matter	Approximate expiration	Litigation relevance
U.S. Patent No. 8,808,737	Extended-release hydrocodone pharmaceutical formulations	September 2027, subject to statutory adjustments	Core formulation patent associated with Zohydro ER
U.S. Patent No. 9,192,644	Hydrocodone extended-release formulation claims	March 2032, subject to statutory adjustments	Later-expiring formulation protection
U.S. Patent No. 9,248,083	Related extended-release opioid formulation technology	2032, subject to statutory adjustments	Associated with the broader Zohydro patent estate, but the case-specific public record should be distinguished from later related actions

The litigation caption identifies Pernix Ireland Pain Ltd. as plaintiff and Actavis Laboratories FL, Inc. as defendant. Pernix Therapeutics and affiliated companies were involved in the commercial development and commercialization of Zohydro ER.

What was Actavis challenging in its ANDA?

Actavis sought FDA approval for a generic extended-release hydrocodone product. Its ANDA included Paragraph IV certifications asserting that the relevant Pernix patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

A Paragraph IV certification is an affirmative patent challenge. Once the innovator receives notice of the certification, it has 45 days to file an infringement action. Pernix filed the Delaware action in February 2016, triggering the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to earlier termination or judicial resolution.

The commercial objective was direct: Actavis sought an FDA approval pathway that could support generic entry before the latest listed patents expired. Pernix sought to preserve the Zohydro ER market through the 2027 and 2032 patent dates.

What was the procedural history of 1:16-cv-00138-GMS?

The action was filed in the U.S. District Court for the District of Delaware and assigned to Judge Gregory M. Sleet under case number 1:16-cv-00138-GMS.

The key procedural events were:

Date	Event
February 2016	Pernix filed the Hatch-Waxman infringement action against Actavis
2016	Actavis defended against infringement and challenged patent validity and enforceability
2016-2018	The parties litigated claim construction, discovery, and the statutory stay implications
2018	The case was resolved without a publicly reported final merits opinion establishing invalidity of the asserted Pernix patents
After resolution	No publicly documented commercial generic launch by Actavis is established in the case record

The case should be distinguished from related Zohydro ER litigation involving other generic applicants, including Alvogen. Decisions in related cases may provide insight into the same patent claims, prior art, and formulation technology, but they do not automatically constitute the judgment in 1:16-cv-00138-GMS.

Did the case produce a final ruling on patent validity?

No publicly reported decision in this specific action establishes that U.S. Patent Nos. 8,808,737 or 9,192,644 were invalid, unenforceable, or not infringed by Actavis.

The available case record indicates that the action ended without a published merits judgment comparable to a full bench-trial opinion. The case therefore provides limited precedential value on the ultimate validity of the Zohydro patent estate. Its primary business significance is the effect of the litigation and resolution on Actavis’s ANDA approval and potential launch timing.

The absence of a merits opinion matters for diligence. A dismissal or settlement does not independently confirm patent validity. It also does not establish that Actavis’s proposed product would have infringed every asserted claim.

Was the Actavis case a Paragraph IV challenge?

Yes. The action was a Hatch-Waxman Paragraph IV dispute arising from Actavis’s ANDA filing for a generic extended-release hydrocodone product.

The principal legal issues in this type of action were:

1. Whether Actavis’s proposed product would infringe the asserted formulation claims.
2. Whether the claims were invalid for anticipation or obviousness.
3. Whether the patents satisfied written-description and enablement requirements.
4. Whether any inequitable-conduct or enforceability defenses applied.
5. Whether the statutory 30-month stay prevented FDA approval during the litigation.

For a formulation patent, infringement analysis typically compares the proposed generic’s active ingredient, release profile, excipient system, dosage form, and manufacturing parameters with the claim limitations. The ANDA’s Paragraph IV notice letter and product-specific disclosure would have controlled the detailed infringement analysis.

What formulation technology did Pernix seek to protect?

The Zohydro patent estate protected extended-release hydrocodone formulations rather than a new hydrocodone molecule. The commercial value therefore depended on formulation design, release kinetics, dosage strength, manufacturability, and regulatory approval.

The relevant technical protection could include:

• Hydrocodone bitartrate as the active pharmaceutical ingredient.
• A controlled-release matrix or delivery system.
• Defined hydrocodone release characteristics.
• Dosage-form architecture and excipient selection.
• Manufacturing processes that produce a reproducible extended-release profile.
• Product-specific limitations that distinguish the formulation from immediate-release hydrocodone products.

Formulation claims can create meaningful barriers even when the active ingredient is old. Their strength depends on whether the claims cover a narrow, technically distinctive formulation or a broad combination that can be designed around.

The Zohydro estate had mixed strategic characteristics. The earlier patent protected the product during the initial commercial period, while later patents potentially extended protection into 2032. The later dates were commercially important, but later-expiring formulation claims are exposed to invalidity and design-around arguments based on known opioid delivery technologies.

How strong was the Pernix patent estate?

The estate was commercially meaningful but not risk-free.

Strengths

The patents covered an approved product rather than an experimental formulation. That fact supported a concrete infringement theory and gave Pernix a defined regulatory asset tied to NDA No. 202880.

The estate also included patents extending beyond the 2027 date of the earlier formulation patent. A generic applicant unable to overcome the later patents could face approval delay until 2032, depending on the scope of the Orange Book listings and the outcome of litigation.

The asserted claims were directed to formulation characteristics that may be difficult to avoid while maintaining the same approved extended-release profile.

Weaknesses

Hydrocodone was a known opioid, and extended-release oral dosage forms were established technologies. Actavis could therefore argue that the claimed formulation was obvious based on combinations of opioid formulation references, release-control systems, and routine formulation optimization.

Generic applicants also commonly challenge:

• The written description of broad formulation claims.
• Enablement across the full scope of the claims.
• Whether the asserted claims actually cover the ANDA product.
• Whether claim limitations are measurable using reproducible testing methods.
• Whether the patent owner improperly listed patents in the Orange Book.

The fact that related Zohydro litigation generated substantive validity disputes shows that the patent estate was subject to material Paragraph IV risk, even though the Actavis action itself did not produce a public merits determination.

What was the Orange Book status of Zohydro ER?

Zohydro ER was listed in the FDA Orange Book with patent information associated with the approved NDA. The relevant patents included formulation patents expiring in 2027 and 2032, subject to patent-term adjustments and any applicable regulatory exclusivity.

The Orange Book listing controlled the Hatch-Waxman framework by giving generic applicants notice of the patents that Pernix considered relevant to the approved product. The listed patents did not guarantee enforcement success. They created the basis for Paragraph IV litigation and the statutory approval stay.

Zohydro ER did not receive biologic exclusivity because it is a small-molecule drug. Biosimilar litigation under the Biologics Price Competition and Innovation Act was therefore not relevant. Any competitive entry would proceed through the ANDA generic pathway, not the biosimilar pathway.

When did Zohydro ER lose exclusivity?

The principal regulatory and patent dates were separate.

Protection type	Relevant date or period
FDA approval	October 2013
Hatch-Waxman 30-month stay from the 2016 lawsuit	Generally extended into 2018 unless earlier terminated
Earlier formulation patent	Approximately September 2027
Later formulation patent	Approximately March 2032
Regulatory exclusivity	No separate biologic exclusivity; product-specific regulatory exclusivity must be evaluated from the NDA record

The practical generic-entry date would depend on the earliest surviving patent, the scope of any settlement, the terms of Actavis’s ANDA approval, and whether other listed patents remained enforceable. Patent expiration alone does not establish the actual launch date.

Did Actavis launch a generic version of Zohydro ER?

The public record for this action does not establish a commercial Actavis launch resulting from the litigation. A settlement or dismissal can prevent immediate entry even when the generic applicant has obtained or later obtains FDA approval.

Potential launch outcomes included:

• No launch until expiration of the relevant patents.
• An authorized generic arrangement.
• A negotiated entry date before patent expiry.
• FDA approval without immediate commercial distribution.
• Product withdrawal or abandonment after commercial reassessment.

No publicly disclosed settlement term should be treated as an agreed Actavis launch date unless it appears in a court-filed agreement, FDA record, or company filing.

What litigation and settlement risks affected Pernix’s business?

The litigation created both legal and commercial risk for Pernix.

A successful Actavis challenge could have led to generic price erosion before 2027 or 2032. Extended-release opioids face additional market risks from prescribing controls, opioid-policy changes, payer restrictions, and declining utilization. Those factors could reduce the value of a patent-protected market even if the patents remain enforceable.

A settlement could preserve near-term exclusivity but transfer value through a license, authorized generic arrangement, royalty, or agreed entry date. The public record does not establish material settlement economics for this action.

Pernix’s broader financial condition also matters. A patent estate may have substantial legal life while the product generates limited revenue because of declining prescriptions, controlled-substance scrutiny, or limited formulary access. Patent value should therefore be assessed against product sales, gross-to-net adjustments, manufacturing cost, and the probability of generic substitution.

How does the Actavis case compare with related Zohydro litigation?

The Actavis case was one part of a wider generic challenge environment for Zohydro ER. Related actions involving other ANDA applicants addressed similar formulation patents and supplied more substantive analysis of obviousness, claim scope, and infringement.

The comparison is important:

Issue	Actavis action	Related Zohydro actions
Product	Generic extended-release hydrocodone	Generic extended-release hydrocodone
Legal pathway	Paragraph IV ANDA litigation	Paragraph IV ANDA litigation
Forum	District of Delaware	District of Delaware
Patent technology	Extended-release hydrocodone formulations	Similar or overlapping formulation claims
Public merits ruling	No definitive public merits holding identified for this action	Some related cases generated substantive patent decisions
Commercial implication	Actavis entry was constrained by litigation resolution	Outcomes informed broader assessment of the Zohydro estate

Related decisions should be used as persuasive technical and legal context, not as a substitute for the docket outcome in 1:16-cv-00138-GMS.

Key Takeaways

• Pernix sued Actavis over an ANDA for generic Zohydro ER.
• The case involved Paragraph IV challenges to Orange Book-listed formulation patents.
• U.S. Patent Nos. 8,808,737 and 9,192,644 were central to the Zohydro patent estate.
• The patents covered extended-release hydrocodone formulations, not a new active ingredient.
• The action did not produce a publicly reported final merits judgment establishing invalidity or infringement.
• Zohydro’s key patent dates extended approximately to 2027 and 2032.
• Biosimilar risk was irrelevant because Zohydro ER is a small-molecule drug.
• No public record identified here establishes an Actavis commercial launch or disclosed settlement economics.
• Related Zohydro cases provide useful context but should not be conflated with the Actavis docket.

FAQs

What was the case number for the Pernix Zohydro litigation against Actavis?

The case number was 1:16-cv-00138-GMS in the U.S. District Court for the District of Delaware.

What is the difference between Zohydro ER patent expiration and FDA exclusivity?

Patent expiration is determined under U.S. patent law and may extend into 2027 or 2032 for the relevant formulation patents. FDA exclusivity is a separate regulatory protection and does not necessarily match the patent term.

Could Actavis have designed around the Pernix Zohydro patents?

Potentially. A design-around would have required a formulation that avoided the asserted claim limitations while satisfying the FDA-approved extended-release profile and other ANDA requirements. The feasibility would depend on the specific claims and Actavis’s disclosed formulation.

Did the Pernix patents cover abuse-deterrent hydrocodone?

The relevant litigation concerned extended-release hydrocodone formulation technology. The existence of formulation patents should not be equated automatically with FDA approval of an abuse-deterrent product or an abuse-deterrent labeling claim.

What was the commercial exposure from a generic Zohydro launch?

The exposure would have included price erosion, payer-driven substitution, reduced prescription volume, and loss of market share. The magnitude cannot be determined from the litigation docket alone because it depends on product sales, market share, generic approval, and launch timing.

References

1. Food and Drug Administration. (2013). Zohydro ER approval letter and prescribing information, NDA 202880. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. Pernix Ireland Pain Ltd. v. Actavis Laboratories FL, Inc., No. 1:16-cv-00138-GMS, U.S. District Court for the District of Delaware.

4. U.S. Patent and Trademark Office. (n.d.). Patent Center and Patent Assignment records for U.S. Patent Nos. 8,808,737 and 9,192,644. U.S. Department of Commerce.

5. 21 U.S.C. § 355(j). (2024). Abbreviated applications for new drugs.